Home > Publications Database > Neutrophils in COVID-19. > print

001     157739
005     20230915092352.0
024 7 _ |a 10.3389/fimmu.2021.652470
|2 doi
024 7 _ |a pmid:33841435
|2 pmid
024 7 _ |a pmc:PMC8027077
|2 pmc
024 7 _ |a altmetric:102734480
|2 altmetric
037 _ _ |a DZNE-2021-01196
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Reusch, Nico
|0 P:(DE-2719)9000843
|b 0
|e First author
|u dzne
245 _ _ |a Neutrophils in COVID-19.
260 _ _ |a Lausanne
|c 2021
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1632221530_9134
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Strong evidence has been accumulated since the beginning of the COVID-19 pandemic that neutrophils play an important role in the pathophysiology, particularly in those with severe disease courses. While originally considered to be a rather homogeneous cell type, recent attention to neutrophils has uncovered their fascinating transcriptional and functional diversity as well as their developmental trajectories. These new findings are important to better understand the many facets of neutrophil involvement not only in COVID-19 but also many other acute or chronic inflammatory diseases, both communicable and non-communicable. Here, we highlight the observed immune deviation of neutrophils in COVID-19 and summarize several promising therapeutic attempts to precisely target neutrophils and their reactivity in patients with COVID-19.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a COVID-19
|2 Other
650 _ 7 |a SARS-CoV-2
|2 Other
650 _ 7 |a clinical trials
|2 Other
650 _ 7 |a granulocytes
|2 Other
650 _ 7 |a neutrophils
|2 Other
650 _ 7 |a scRNA-seq
|2 Other
650 _ 7 |a viral infection
|2 Other
650 _ 2 |a COVID-19: epidemiology
|2 MeSH
650 _ 2 |a COVID-19: immunology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neutrophils: immunology
|2 MeSH
650 _ 2 |a Pandemics
|2 MeSH
650 _ 2 |a SARS-CoV-2: immunology
|2 MeSH
700 1 _ |a De Domenico, Elena
|0 P:(DE-2719)9000846
|b 1
|u dzne
700 1 _ |a Bonaguro, Lorenzo
|0 P:(DE-2719)9001512
|b 2
|u dzne
700 1 _ |a Schulte-Schrepping, Jonas
|0 P:(DE-2719)9001500
|b 3
|u dzne
700 1 _ |a Baßler, Kevin
|0 P:(DE-2719)9000836
|b 4
|u dzne
700 1 _ |a Schultze, Joachim L
|0 P:(DE-2719)2811660
|b 5
|u dzne
700 1 _ |a Aschenbrenner, Anna Christin
|0 P:(DE-2719)2812913
|b 6
|e Last author
|u dzne
773 _ _ |a 10.3389/fimmu.2021.652470
|g Vol. 12, p. 652470
|0 PERI:(DE-600)2606827-8
|p 652470
|t Frontiers in immunology
|v 12
|y 2021
|x 1664-3224
856 4 _ |u https://www.frontiersin.org/articles/10.3389/fimmu.2021.652470/full
856 4 _ |u https://pub.dzne.de/record/157739/files/19422.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/157739/files/19422.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:157739
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000843
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000846
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9001512
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001500
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000836
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811660
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2812913
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
914 1 _ |y 2021
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT IMMUNOL : 2021
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-11T10:28:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-11T10:28:02Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-05-11T10:28:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-23
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT IMMUNOL : 2021
|d 2022-11-23
920 1 _ |0 I:(DE-2719)1013031
|k Schultze - PRECISE
|l United epigenomic platform
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000031
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21